Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
Fourteen patients with advanced ovarian epithelial carcinoma were treated with a combination of chemotherapy and immunotherapy. The chemotherapy consisted of either melphalan or a combination of adriamycin, cytoxan, and cisplatin. The immunotherapy consisted of the injection of autologous radiation-attenuated tumor and Corynebacterium parvum. No significant toxicity occurred as a result of the immunotherapy, and there was no evidence of tumor growth at the sites of injection. The autologous tumor skin test showed prognostic value. Skin testing with C parvum was of less prognostic value than tumor. All other studies of immunologic status, including T- and B-cell enumeration and blastogenic responsiveness of the patients' lymphocytes to autologous tumor and mitogens, were of no prognostic value.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D011425:Propionibacterium acnes / Q000276:immunology*; D012882:Skin Tests
D001428:Bacterial Vaccines; D008558:Melphalan